(Q45423758)

English

Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

oncolytic virus

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Samuel D Rabkin

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Varghese S

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Liu R

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Nielsen PG

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Ipe T

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Martuza RL

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

1 March 2006

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Cancer Gene Therapy

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

253-265

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700900

0 references

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Novel therapeutic strategies for androgen-independent prostate cancer: an update

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Conditionally replicating herpes vectors for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Oncolytic herpes simplex virus vectors for cancer virotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Prostate cancer in a transgenic mouse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Development and characterization of a mouse prostate adenocarcinoma cell line: ductal formation determined by extracellular matrix

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Expression, specificity and immunotherapy potential of prostate-associated genes in murine cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Antigen presentation by MHC class I and its regulation by interferon gamma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Correlation between major histocompatibility complex class I molecules and CD8+ T lymphocytes in prostate, and quantification of CD8 and interferon-gamma mRNA in prostate tissue specimens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Molecular characterization of defective antigen processing in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Genetics of natural resistance to herpesvirus infections in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Cytokines in cancer immunity and immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Interleukin-12 and the regulation of innate resistance and adaptive immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Immune surveillance against a solid tumor fails because of immunological ignorance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Thyroid cancer immuno-therapy with retroviral and adenoviral vectors expressing granulocyte macrophage colony stimulating factor and interleukin-12 in a rat model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

A single intratumoral injection of a fiber-mutant adenoviral vector encoding interleukin 12 induces remarkable anti-tumor and anti-metastatic activity in mice with Meth-A fibrosarcoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Augmentation of antitumor immune responses by multiple intratumoral inoculations of replication-conditional HSV and interleukin-12.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Complete tumor prevention by engineered tumor cell vaccines employing nonviral vectors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

21 January 2018

Cancer as a robust system: implications for anticancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of tumor evasion from the immune response.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Advances in immunotherapyfor prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: association with progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased incidence of pathological and clinical prostate cancer with age: age related alterations of local immune surveillance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Loss of HLA class I expression in prostate cancer: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin 12 secretion enhances antitumor efficacy of oncolytic herpes simplex viral therapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

IL-12 deaths: explanation and a puzzle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700900

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.CGT.7700900

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16179929%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45423758&oldid=1856257296"